Patents by Inventor Stefaan Rossenu

Stefaan Rossenu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating rheumatoid arthritis by administering IL-6 receptor antibodies
    Patent number: 11149089
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: October 19, 2021
    Assignee: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
  • PROLONGED INHIBITION OF INTERLEUKIN-6 MEDIATED SIGNALING
    Publication number: 20190119393
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: October 2, 2018
    Publication date: April 25, 2019
    Applicant: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
  • Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
    Patent number: 10138302
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: November 27, 2018
    Assignee: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
  • PROLONGED INHIBITION OF INTERLEUKIN-6 MEDIATED SIGNALING
    Publication number: 20150050268
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: September 24, 2012
    Publication date: February 19, 2015
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Ozkan Yalkinoglu
  • PROLONGED INHIBITION OF INTERLEUKIN-6 MEDIATED SIGNALING
    Publication number: 20140212417
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: September 24, 2012
    Publication date: July 31, 2014
    Applicant: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu